November was a month of optimism and market recovery, catalysed by multiple positive announcements on Covid vaccines and the tortuous, but eventually clear, outcome of the US election. Despite both events being well flagged in advance, they contained enough new positive news to meaningfully improve risk sentiment and spark big rallies in depressed assets across the globe.
“The 95% efficacy of the Pfizer/BioNtech drug was startlingly high and a positive surprise which gave a real boost to risk sentiment across asset classes”
At the start of the month one would have thought that it would take an awful lot to push the outcome of the most partisan US election in history into second place in terms of market impact, but the early November announcement from Pfizer of trial results for their Covid vaccine did exactly that. Although vaccines had been expected by investors, the 95% efficacy of the Pfizer/BioNtech drug was startlingly high and a positive surprise which gave a real boost to risk sentiment across asset classes. This boost was amplified by similar announcements from Moderna a week later and then finally by AstraZeneca towards month end. The recent approval for the Pfizer vaccine and further anticipated approvals from regulatory authorities in the next few days and weeks should allow vaccination programmes to begin this side of Christmas, and the journey back to normality to finally begin.
To be honest, investors could and did see this series of events coming, but given the potential for a negative outcome, few had positioned too aggressively ahead of the actual announcements. ‘Covid loser’ sectors such as the travel and leisure, or entire markets like the UK, stuffed full of ‘old economy’ names, had few friends for most of 2020 and that remained consistent as we entered the penultimate month of the year.
“A Biden Presidency balanced by a likely Republican Senate was eventually assessed to be the best of both worlds for markets”
The vaccine news changed all that, particularly the first announcement, backed up by the gradual acceptance of the US election outcome. A Biden Presidency balanced by a likely Republican Senate was eventually assessed to be the best of both worlds for markets, as it removed a chaotic
Trump administration without handing untrammelled power to the ‘reforming’ incomers. Market ‘unfriendly’ Biden policies are much less likely to pass in their purest form now, allowing US markets to breathe a little easier, whilst pricing in the additional good news on Covid vaccines.